How a 20-Year Old Asthma Drug Is Boosting Food Allergy Research

Why It Matters

Repurposing an existing asthma drug shortens development timelines and lowers costs, offering a near‑term solution to the growing food‑allergy crisis. Successful trials could shift industry focus from symptom management to durable tolerance therapies.

Key Takeaways

• Asthma drug Xolair shows promise in food allergy trials
• FDA approves first oral immunotherapy for peanut allergy
• Study reduces severe reactions by 70% in participants
• Repurposing cuts development costs and speeds market entry
• Researchers aim for broader allergy applications beyond peanuts

Pulse Analysis

Food allergies have surged in the United States, affecting an estimated 8 percent of children and prompting schools to ban peanuts and parents to carry emergency epinephrine. Traditional management relies on avoidance and rescue medication, leaving a gap for therapies that can modify the immune response. This unmet need has driven scientists to explore novel approaches, including biologics originally designed for unrelated conditions, to create lasting tolerance rather than merely treating symptoms.

Enter Xolair, a monoclonal antibody approved two decades ago for moderate‑to‑severe asthma. By binding to immunoglobulin E (IgE), Xolair dampens the allergic cascade that triggers airway constriction. Researchers discovered that the same IgE‑blocking mechanism can blunt the immune reaction to food proteins when paired with controlled oral exposure. Recent trials integrating Xolair with peanut oral immunotherapy reported a 70 percent reduction in severe reactions, accelerating desensitization timelines and improving safety profiles. Leveraging an existing, FDA‑approved drug sidesteps many early‑stage safety hurdles, slashing development costs and expediting regulatory pathways.

The implications extend beyond peanuts. If Xolair’s success translates to other allergens such as tree nuts, shellfish, or dairy, the biotech sector could witness a wave of repurposed biologics targeting food allergy. This would attract investment, stimulate competition, and potentially lower treatment costs for families. Moreover, the FDA’s recent approval of the first oral immunotherapy signals a regulatory openness to combination biologic strategies, paving the way for broader adoption. As clinicians gain confidence in these hybrid protocols, the market may shift toward integrated allergy management solutions that promise both immediate safety and long‑term immune tolerance.